Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy

Area of Science:

• Immunology
• Pulmonology
• Genetics

Background:

• Agammaglobulinaemia is a primary immunodeficiency characterized by low immunoglobulin levels.
• Immunoglobulin replacement therapy (IRT) is standard care, improving survival and reducing infections.
• However, chronic lung disease, including bronchiectasis, can still develop in these patients.

Purpose of the Study:

• To investigate the prevalence and risk factors for bronchiectasis and deteriorating lung function in patients with agammaglobulinaemia receiving IRT.
• To identify factors associated with the development of chronic lung disease despite standard treatment.

Main Methods:

• Retrospective case study of 139 patients with agammaglobulinaemia from the UK Primary Immune Deficiency (UKPID) registry.
• Analysis of clinical and laboratory data, including age at diagnosis, type of IRT (intravenous vs. subcutaneous), history of pneumonia, and lung function tests.
• Multivariate analysis to identify significant risk factors for bronchiectasis.

Main Results:

• 56% of patients had radiological evidence of bronchiectasis.
• Significant risk factors for bronchiectasis included being over 18 years old, a history of pneumonia, and receiving intravenous immunoglobulin (IVIG) over subcutaneous immunoglobulin (SCIG).
• Patients with bronchiectasis had significantly poorer lung function (FEV1) compared to those without.

Conclusions:

• Agammaglobulinaemia patients on IRT remain at high risk for developing chronic lung disease and progressive lung function decline.
• Early initiation of IRT and potentially optimizing the route of administration may be crucial.
• Further strategies are needed to prevent and manage lung complications in this population.